» Articles » PMID: 32454831

Retrospective Descriptive Analysis of West Nile Neuroinvasive Disease (WNND) in Northwest Louisiana

Overview
Journal Int J Microbiol
Publisher Wiley
Specialty Microbiology
Date 2020 May 27
PMID 32454831
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The aim of the study was to describe the presentation characteristics and epidemiology of WNND in Louisiana to improve future recognition of cases and decrease inappropriate antibiotic use. . It was a retrospective descriptive-analytic cohort study. A total of 23 patients with WNND were identified at one tertiary care hospital center in Northwest Louisiana from a retrospective chart review from January 1, 2012 to October 31, 2017.

Results: The median age was 49 years (range: 15-75) for patients with WNND. Of 23 patients diagnosed with WNND, twelve (52%) were diagnosed with encephalitis (WNE), six (26%) were diagnosed with meningitis (WNM), and five (22%) with myelitis (WNME). The common symptoms with WNND were fever in 65%, altered mental status in 61%, headache in 52%, fatigue in 43%, gastrointestinal symptoms in 43%, rigors in 30%, imbalance in 26%, rash in 9%, and seizures in 26% of patients. Most patients presented in the late summer season. The average duration of antibiotics given was six days. The average number of days from the admission to the diagnosis of WNND was nine days (3 to 16 days). Twenty-one (91%) patients survived the infection.

Conclusions: Identifying WNV infection early in its clinical course would help in decreasing inappropriate antibiotic use when patients presented with fever and meningeal symptoms. Performing WNV serology in CSF studies is critical in making the diagnosis.

Citing Articles

Clinical and Diagnostic Features of West Nile Virus Neuroinvasive Disease in New York City.

Roberts J, Kim C, Dean A, Kulas K, St George K, Hoang H Pathogens. 2024; 13(5).

PMID: 38787234 PMC: 11123700. DOI: 10.3390/pathogens13050382.


Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients.

Koch M, Pozsgai E, Soos V, Nagy A, Giran J, Nyisztor N BMC Infect Dis. 2021; 21(1):65.

PMID: 33441090 PMC: 7805165. DOI: 10.1186/s12879-020-05760-7.

References
1.
Sugumaran R, Larson S, DeGroote J . Spatio-temporal cluster analysis of county-based human West Nile virus incidence in the continental United States. Int J Health Geogr. 2009; 8:43. PMC: 2717929. DOI: 10.1186/1476-072X-8-43. View

2.
Wang T, Anderson J, Magnarelli L, Wong S, Koski R, Fikrig E . Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol. 2001; 167(9):5273-7. DOI: 10.4049/jimmunol.167.9.5273. View

3.
Iyer A, Kousoulas K . A review of vaccine approaches for West Nile virus. Int J Environ Res Public Health. 2013; 10(9):4200-23. PMC: 3799512. DOI: 10.3390/ijerph10094200. View

4.
. Intrauterine West Nile virus infection--New York, 2002. MMWR Morb Mortal Wkly Rep. 2003; 51(50):1135-6. View

5.
Kelley T, Prayson R, Ruiz A, Isada C, Gordon S . The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature. Am J Clin Pathol. 2003; 119(5):749-53. DOI: 10.1309/PU4R-76JJ-MG1F-81RP. View